adMare
News

June 07 2022

adMare Porfolio Company Find Therapeutics Signs Licensing agreement to Develop a Promising New Therapy for Multiple Sclerosis and Other Demyelinating Diseases

Find Therapeutics Inc. (Montreal, Quebec) and SATT Conectus (Strasbourg, France) have signed an exclusive worldwide license to develop a promising therapy for Multiple Sclerosis (MS) and Optic Neuritis (ON) based on a new class of compounds.

Read

June 07 2022

adMare Portfolio Company FORUS Therapeutics Announces XPOVIO® (selinexor) Is Authorized for Sale by Health Canada

FORUS Therapeutics Inc ("FORUS”), is pleased to announce that on May 31, 2022 XPOVIO® (selinexor) was authorized for sale by Health Canada in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.

Read

June 01 2022

Anie Perrault joins adMare as Vice President, Public Affairs and Communications

adMare is pleased to announce the appointment of Anie Perrault, LL.L, ASC as Vice President, Public Affairs and Communications.

Read

May 18 2022

adMare Appoints Dr. Christine Allen as Vice-President, Ecosystem Development

Toronto May 18, 2022 – adMare BioInnovations is pleased to announce the appointment of Dr. Christine Allen as Vice-President, Ecosystem Development. Dr. Allen will continue adMare’s leadership of Canada’s strong…

Read

May 10 2022

adMare BioInnovations joins a $42m Series A financing in Domain Therapeutics

Strasbourg, France – Montreal, Canada – May 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in…

Read

May 02 2022

adMare Portfolio Company, Zucara Therapeutics Secures Additional Funding for the Development of ZT-01

Toronto, Canada, May 2, 2022 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that…

Read

April 22 2022

Join Us on May 30th, for the Official Opening of adMare’s Montreal Innovation Centre Expansion & BIOQuébec’s 2022 AGA

adMare BioInnovations and BIOQuébec cordially invite you to join your fellow Quebec life sciences leaders for a very special evening to celebrate the official opening of adMare’s new facility. Special guests will…

 

Read

April 12 2022

Read the newest issue of the adMare Quarterly newsletter – April 12, 2022

adMare Quarterly It has been a busy few months at adMare! From a transformative investment of $92M recently announced by the Minister of Innovation, Science and Industry at our Innovation…

Read

April 08 2022

Building Canada’s Life Sciences Industry on a Strong Foundation of Canadian Talent

Labour shortages are hitting virtually every Canadian sector, from coffee shops to car manufacturing – and life sciences is no exception. But what is exceptional about our industry is its…

Read

April 05 2022

adMare BioInnovations Collaborates with Accelerator Company, Molecular Forecaster Inc. on Computational Approaches to Drug Discovery

MONTREAL, QUEBEC, April 5, 2022 – Molecular Forecaster Inc. (MFI) is excited to announce a partnership with adMare BioInnovations (adMare) to deliver computer-aided drug design (CADD) resources to selected R&D…

Read

March 30 2022

Government of Canada Invests $92 million in adMare to help translate health research into innovative new therapies in Canada

GOVERNMENT OF CANADA RELEASE Government of Canada advances domestic life sciences sector by supporting Canadian companies, talent, and research and development March 30, 2022 – Vancouver, British Columbia –…

Read

March 16 2022

Listen to adMare’s President & CEO, Gordon C. McCauley on CGEn’s New Podcast, Synapsis

adMare’s President & CEO, Gordon C. McCauley speaks with Dr. Naveed Aziz on the first episode of CGEn’s new podcast, Synapsis, about the health sciences sector and what can be…

Read

March 11 2022

adMare supports Ukraine; Responds to Ministers Champagne and Duclos

Today, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, and the Honourable Jean-Yves Duclos, Minister of Health issued a statement on additional measures in response to Vladimir Putin’s…

Read

March 08 2022

Join Us For adMare’s Lunch & Learn: Building Talent with Amplitude Ventures March 17, 2022

The Amplitude Fellowship – Training the next generation of life science entrepreneurs Are you an outstanding life science focused PhD candidate, post doc, MD, or inventor? Do you want to…

Read

March 08 2022

Join Us For adMare’s Global Leaders Webinar Featuring Dr. Robert Langer April 19, 2022

adMare Global Leaders Webinar From Lab bench to clinic: How to solve global health challenges by developing new therapies through innovation and founding new companies Featuring Dr. Robert Langer adMare’s…

Read

February 14 2022

adMare Portfolio Company, Find Therapeutics, Appoints Dr. Philippe Douville as Chief Executive Officer

MONTREAL, Feb. 14, 2022 – Find Therapeutics Inc. (‘Find’) is pleased to announce accomplished biotechnology executive and entrepreneur, Dr. Philippe Douville as its new Chief Executive Officer. Dr. Douville brings to Find 25…

Read

February 08 2022

adMare Portfolio Company, Zucara Therapeutics Announces Publication of Preclinical Study

Toronto, Canada, February 8, 2022 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that…

Read

January 17 2022

Inversago Pharma, an adMare Portfolio Company, Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and Provides Strategy Update

MONTREAL, Jan. 17, 2022 –Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the Phase 1 Clinical Trial for its INV-202 molecule that focuses…

Read

January 13 2022

adMare Portfolio Company NIMIUM Therapeutics’ Research Breakthrough Shows Promise To Maintain Good Health As We Age

MONTREAL, Jan. 11, 2022 – New research published in Nature Communications suggests that a newly-identified enzyme could reduce sugar and fat in the body and help us live longer healthier lives. The enzyme, Glycerol-3-Phosphate…

Read

January 12 2022

adMare Portfolio Company Neurasic Therapeutics Receives New Grant to Advance Non-Opioid Pain Treatment

Montréal – Québec – January 12th, 2022 –CQDM is pleased to announce a grant for a collaboration between McGill University, Neurasic Therapeutics, McGill University’s Healthy Brains, Healthy Lives (HBHL) initiative…

Read

December 21 2021

adMare Quarterly

In this issue of adMare Quarterly, we are pleased to share our latest news on building companies, building ecosystems, and building talent to build the Canadian life sciences industry from sea to sea – along with Season’s Greetings and a look back on some 2021 highlights from adMare.

Read

December 16 2021

Specific Biologics Closes Seed Financing with Industry Leaders Lumira Ventures and adMare BioInnovations

Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase™ platform gene editors to build a pipeline of treatments for serious genetic diseases. Toronto, Ontario, Canada [December…

Read

December 15 2021

Join Us for adMare’s Industry Builder Webinar Featuring Dr. Michel Bouvier – Jan. 17, 2022

Functional selectivity of GPCR signaling and its spatio-temporal propagation; Toward the design of better drugs? Join us for adMare’s Industry Builder Webinar Series, featuring Dr. Michel Bouvier. Dr. Bouvier…

Read

November 18 2021

adMare BioInnovations Announces Successful Applicants to 2021-2022 Executive Institute

Vancouver, BC and Montreal, QC (November 18, 2021) – adMare BioInnovations is pleased to announce the nine women and nine men from diverse backgrounds and representing a wide range of…

Read

November 15 2021

adMare BioInnovations and uOttawa Work Together to Translate University Research into Strong New Canadian Life Science Companies

Vancouver, BC, and Ottawa, ON (November 15, 2021) – adMare BioInnovations is pleased to announce a collaboration with the University of Ottawa to bring new resources and focus to the…

Read

November 09 2021

adMare BioInnovations and CASTL Partner to Build Canada’s Biomanufacturing Talent

Vancouver, BC and Charlottetown, PEI (November 9, 2021) – adMare BioInnovations and the Canadian Alliance for Skills and Training in Life Sciences (CASTL) are pleased to announce their new partnership…

Read

November 02 2021

adMare BioInnovations and District 3 Innovation partner to provide science-based Canadian startups more cohesive support to grow into industry leaders

MONTREAL, Quebec – November 2, 2021: District 3 Innovation Hub, an early-stage startup incubator located at Concordia University, and adMare BioInnovations, a Canadian life sciences leader that builds the industry…

Read

October 21 2021

adMare’s President & CEO Gordon C. McCauley is Appointed to BIOVECTRA Board of Directors

Charlottetown, P.E.I. (October 21, 2021) – BIOVECTRA, a leading Canadian biotech and pharmaceutical CDMO has appointed Gordon C. McCauley, President and CEO of adMare BioInnovations and Steven Klosk CEO (retired) Cambrex…

Read

September 28 2021

adMare’s Accelerate Quebec Company, Molecular Forecaster, Continues Quest to Fast Track Drug Discovery with Two New Public-Private Partnerships

The company and its partners have secured CAD$1 million to apply and improve MFI’s virtual drug-design software in support of preclinical research targeting antibiotic-resistant bacteria and non-alcoholic fatty liver disease…

Read

September 17 2021

adMare Portfolio Company, Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202, a Next Generation Peripherally-acting CB1 Blocker

MONTREAL (CANADA) – September 7th, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL)…

Read

September 13 2021

adMare Portfolio Company BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough

LAVAL, Quebec–(BUSINESS WIRE)–Sep. 13, 2021– BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related…

Read

July 06 2021

New life sciences company takes aim at obesity, toxic effects of overnutrition — NIMIUM Therapeutics launches in Montreal

A new made-in-Canada life sciences company, NIMIUM Therapeutics, has been launched to develop novel therapies for patients with cardiometabolic diseases. The company’s foundational technology is based on the cutting-edge research…

Read

June 03 2021

CPDC/adMare Radiopharmaceutical Initiative (CARI): New blog post – Q&A session with our experts

Over the past few months, adMare BioInnovations and the Centre for Probe Development and Commercialization (CPDC) have shared with you information about the role and the potential of radiopharmaceuticals in…

Read

May 17 2021

adMare and AazeinTx Inc Sign Global Exclusive Agreement

adMare BioInnovations (“adMare”) and AazeinTx Inc. (“AazeinTx”) have closed a global exclusive licensing transaction for a promising acute asthma treatment. Under the agreement, AazeinTx has acquired all rights to NEO6860,…

Read

April 12 2021

adMare BioInnovations launches Canada’s first & only digital life sciences community

In our COVID world, we all need to get creative in building new ways to safely and effectively come together. The pandemic is showing us that Canada needs strong life sciences…

Read

February 10 2021

Discover the Medical Isotope & Radiopharmaceutical Landscape in Canada

Did you know that Canada has been a global leader in the research, development and production of medical isotopes as well as radiopharmaceuticals for more than 60 years? Many people…

Read

February 10 2021

Soundbite Medical Solutions Announces Health Canada Approval for SoundBite® Crossing System ‐ Peripheral (14P)

Soundbite announces Health Canada Approval for SoundBite Crossing System ‐ Peripheral (SCS-P) with the 0.014” Active Wire (14P). The SCS-P (14P) is intended for the treatment of patients suffering from peripheral…

Read

January 27 2021

New Canadian Pharmaceutical Company Brings Novel Cancer Therapies To Market

FORUS Therapeutics launches today, bringing a new pharmaceutical company onto the Canadian landscape. With a highly-experienced and proven team, an FDA-approved product already in its pipeline, and significant financial investment…

Read

January 14 2021

adMare Launches Abdera with AbCellera as a Founding Partner

adMare BioInnovations, Canada’s global life sciences venture, is pleased to announce the launch of Abdera Therapeutics Inc. (Abdera) with founding partner, AbCellera (Nasdaq: ABCL). Abdera is a precision oncology company…

Read

December 11 2020

Join us in the 50 – 30 Challenge

adMare is proud to be an early adopter of the Government’s 50 – 30 Challenge to accelerate diversity and inclusion in our workforce at the senior leadership level. To build…

Read

December 10 2020

adMare BioInnovations Welcomes the First Quebec Start-Ups in its Accelerate Program

adMare today unveiled the six companies selected under its new acceleration program supported by the Quebec Government and the City of Montreal. Montréal, QC – December 10, 2020 – adMare BioInnovations,…

Read

December 02 2020

Event: Announcement of the Companies Selected Under adMare Accelerate Program

adMare BioInnovations, Canada’s global life sciences venture, invites you to join us on Thursday, December 10 at 11:00 am (EST), for the unveiling of the six exciting start-ups selected for our new…

Read

November 26 2020

adMare’s cross-Canada virtual roadtrip – British Columbia Stop

COVID-19 may be keeping us from getting on planes and meeting in person, but it’s not stopping us from continuing to build Canada’s life sciences industry from sea to sea,…

Read

November 26 2020

Radiopharmaceuticals: a new class of drugs for cancer patients, and a new road for Canada to lead global life sciences

The role of radiopharmaceuticals in health care may still be quite a mystery for many Canadians, but this area has a tremendous therapeutic and commercial potential in our country. Canada…

Read

November 16 2020

Developing Canada’s Next Generation of Commercial Life Scientists

adMare Academy Responds to Pandemic with New Pan-Canadian BioInnovation Scientist Program November 16, 2020: adMare BioInnovations, Canada’s global life sciences venture, is proud to announce the launch of its new…

Read

November 02 2020

Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes

The proceeds from the financing will fund Phase 1 & Phase 2 clinical trials of ZT-01, Zucara’s first-in-class drug candidate designed to prevent hypoglycemia in Type 1 Diabetes (T1D), a frequent, unintended consequence of insulin therapy for people with T1D & other types of insulin-dependent diabetes.

Read

October 15 2020

Didier Leconte Elected Chair of adMare Board

Vancouver and Montréal, Canada – October 15, 2020: adMare BioInnovations, Canada’s global life sciences venture, is pleased to announce the election of Mr. Didier Leconte, Vice President, Investments – Life Sciences…

Read

September 30 2020

Pave the road to successful commercialization of your radiopharmaceutical innovation with CARI – The CPDC & adMare Radiopharmaceutical Initiative

If you are an academic researcher or a biotech company looking to pave the road to successful commercialization of your radiopharmaceutical innovation, join us on October 15th, 2020. What is CARI?…

Read
1 2